Log in

Relevant bibliographies by topics / Nasal Potential Difference Measurament / Journal articles

Journal articles on the topic 'Nasal Potential Difference Measurament'

To see the other types of publications on this topic, follow the link: Nasal Potential Difference Measurament.

Author: Grafiati

Published: 11 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Nasal Potential Difference Measurament.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Uwaifo, Omotola, Penelope Bamford, Pamela L. Zeitlin, and Carol J. Blaisdell. "Acidic pH Hyperpolarizes Nasal Potential Difference." Pediatric Pulmonology 41, no. 2 (February 2006): 151–57. http://dx.doi.org/10.1002/ppul.20328.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Sermet-Gaudelus, I., D. Roussel, F. Huet, S. Bui, E. Deneuville, M. Guillot, R. Abboutaam, et al. "369* Nasal potential difference in hypertrypsinemic children." Journal of Cystic Fibrosis 6 (June 2007): S90. http://dx.doi.org/10.1016/s1569-1993(07)60339-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Vermeulen, F., N. Feyaerts, M. Proesmans, and K. De Boeck. "31 Modified nasal catheter for measurement of nasal potential difference improves reproducibility." Journal of Cystic Fibrosis 10 (June 2011): S8. http://dx.doi.org/10.1016/s1569-1993(11)60052-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Vermeulen, F., J. Ophoff, M. Proesmans, L. J. Dupont, and K. De Boeck. "49 Modified nasal catheter for measurement of nasal potential difference improves repeatability." Journal of Cystic Fibrosis 11 (June 2012): S68. http://dx.doi.org/10.1016/s1569-1993(12)60218-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Bronsveld, Inez, François Vermeulen, Dorotha Sands, Teresinha Leal, Anissa Leonard, Paola Melotti, Yasmin Yaakov, et al. "Influence of perfusate temperature on nasal potential difference." European Respiratory Journal 42, no. 2 (October 25, 2012): 389–93. http://dx.doi.org/10.1183/09031936.00097712.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Chung, Nancy C., Beate Illek, Jonathan H. Widdicombe, and Horst Fischer. "Measurement of Nasal Potential Difference in Mild Asthmatics." Chest 123, no. 5 (May 2003): 1467–71. http://dx.doi.org/10.1378/chest.123.5.1467.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Domingo-Ribas, C., and M. Bosque-García. "Nasal Potential Difference Test to Diagnose Cystic Fibrosis." Archivos de Bronconeumología ((English Edition)) 42, no. 1 (January 2006): 33–38. http://dx.doi.org/10.1016/s1579-2129(06)60111-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Ng, Ronny Tah Yen, Fernando Augusto de Lima Marson, Jose Dirceu Ribeiro, Antonio Fernando Ribeiro, Carmen Silvia Bertuzzo, Maria Angela Gonçalves de Oliveira Ribeiro, Silvana Dalge Severino, and Eulalia Sakano. "Nasal Potential Difference in Cystic Fibrosis considering SevereCFTRMutations." Disease Markers 2015 (2015): 1–11. http://dx.doi.org/10.1155/2015/306825.

Full text

Abstract:

The gold standard for diagnosing cystic fibrosis (CF) is a sweat chloride value above 60 mEq/L. However, this historical and important tool has limitations; other techniques should be studied, including the nasal potential difference (NPD) test.CFTRgene sequencing can identifyCFTRmutations, but this method is time-consuming and too expensive to be used in all CF centers. The present study compared CF patients with two classes I-IIICFTRmutations (10 patients) (G1), CF patients with classes IV-VICFTRmutations (five patients) (G2), and 21 healthy subjects (G3). The CF patients and healthy subjects also underwent the NPD test. A statistical analysis was performed using the Mann-Whitney, Kruskal-Wallis,χ2, and Fisher’s exact tests,α=0.05. No differences were observed between the CF patients and healthy controls for the PDMax, Δamiloride, and Δchloride + free + amiloride markers from the NPD test. For the finger value, a difference between G2 and G3 was described. The Wilschanski index values were different between G1 and G3. In conclusion, our data showed that NPD is useful for CF diagnosis when classes I-IIICFTRmutations are screened. However, if classes IV-VI are considered, the NPD test showed an overlap in values with healthy subjects.

APA, Harvard, Vancouver, ISO, and other styles

9

Schüler, Daniel, Isabelle Sermet-Gaudelus, Michael Wilschanski, Manfred Ballmann, Michèle Dechaux, Aleksander Edelman, Martin Hug, et al. "Basic protocol for transepithelial nasal potential difference measurements." Journal of Cystic Fibrosis 3 (August 2004): 151–55. http://dx.doi.org/10.1016/j.jcf.2004.05.032.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Graham, Scott M., Shaun N. Scott, Janice Launspach, and Joseph Zabner. "The Effects of Fluticasone Propionate on Nasal Epithelial Potential Difference." American Journal of Rhinology 16, no. 3 (May 2002): 145–49. http://dx.doi.org/10.1177/194589240201600304.

Full text

Abstract:

Background Human airway epithelium maintains homeostasis of the fluid and salt composition at the airway surface by a regulated transport of sodium and chloride ions. The volume and composition of airway surface liquid have been shown to be important in the pathogenesis of cystic fibrosis, nasal inflammatory disease, and nasal polyposis. The presence of functional epithelial sodium and chloride channels in the airway epithelium can be evaluated electrically by measuring the voltage across the nasal epithelium (Vt). Because fluticasone propionate is commonly used to treat nasal inflammatory diseases, we tested its effect on the nasal ion transport. Methods A single-blind prospective trial was performed on 12 healthy volunteers. Subjects were randomized to receive either fluticasone propionate or normal saline nasal spray twice daily for 2 weeks. We measured the nasal voltage at baseline, days 3 and 14, and 2 weeks after cessation of treatment. The basal voltage, the change in voltage after perfusion with amiloride (sodium channel blocker), and the change in voltage after perfusion with isoproterenol in a low-chloride buffer (chloride channel activator) were recorded. Saccharin clearance times were measured also. Results Two-week treatment with fluticasone propionate resulted in a significant increase in the change in Vt after perfusion with amiloride. There was no significant change in the group treated with normal saline. These findings also were observed on day 3 and were reversed completely after the 2-week washout period. The increase in amiloride-sensitive Vt did not result in a decrease in mucociliary clearance. Conclusions This study suggests that one effect of fluticasone propionate use on nasal mucosa in normal volunteers is increased epithelial sodium absorption.

APA, Harvard, Vancouver, ISO, and other styles

11

STEWART, ELEANOR J., MICHAEL J. CINNAMOND, PAUL NICHOLLS, and C. FRED STANFORD. "The effects of diuretics on nasal transmucosal potential difference." Clinical Otolaryngology 17, no. 4 (August 1992): 351–53. http://dx.doi.org/10.1111/j.1365-2273.1992.tb01011.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Cohen, M., Y. Yaakov, H. Friedman, D. Shoseyov, M. Cohen-Cymberknoh, E. Kerem, and M. Wilschanski. "26 Nasal potential difference in young children is feasible." Journal of Cystic Fibrosis 16 (June 2017): S70. http://dx.doi.org/10.1016/s1569-1993(17)30391-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Cinell, G., M. Sevgili, D. Balkancy, I. Karabulut, D. Dogru, E. Yalcin, N. Cobanoglu, et al. "483 Nasal potential difference measurements in Turkish CF patients." Journal of Cystic Fibrosis 5 (2006): S106. http://dx.doi.org/10.1016/s1569-1993(06)80407-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Yaakov, Yasmin, Eitan Kerem, Yaakov Yahav, Joseph Rivlin, Hannah Blau, Lea Bentur, Micha Aviram, Elie Picard, Tali Bdolah-Abram, and Michael Wilschanski. "Reproducibility of Nasal Potential Difference Measurements in Cystic Fibrosis." Chest 132, no. 4 (October 2007): 1219–26. http://dx.doi.org/10.1378/chest.06-2975.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Mairbäurl, Heimo, Jörn Weymann, Andreas Möhrlein, Erik R. Swenson, Marco Maggiorini, J. Simon R. Gibbs, and Peter Bärtsch. "Nasal Epithelium Potential Difference at High Altitude (4,559 m)." American Journal of Respiratory and Critical Care Medicine 167, no. 6 (March 15, 2003): 862–67. http://dx.doi.org/10.1164/rccm.200208-864oc.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Baker, E., X. Jeunemaitre, A. J. Portal, P. Grimbert, N. Markandu, A. Persu, P. Corvol, and G. MacGregor. "Abnormalities of nasal potential difference measurement in Liddle's syndrome." Journal of Clinical Investigation 102, no. 1 (July 1, 1998): 10–14. http://dx.doi.org/10.1172/jci1795.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Procianoy, Elenara da Fonseca Andrade, Fernando Antônio de Abreu e Silva, Paulo José Cauduro Maróstica, and Paul M. Quinton. "Chloride Conductance, Nasal Potential Difference and Cystic Fibrosis Pathophysiology." Lung 198, no. 1 (November 16, 2019): 151–56. http://dx.doi.org/10.1007/s00408-019-00293-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Peckham, D. G., A. Conn, C. Chotai, S. Lewis, and A. J. Knox. "Effect of Oral Digoxin, Topical Ouabain and Salbutamol on Transepithelial Nasal Potential Difference in Patients with Cystic Fibrosis." Clinical Science 89, no. 3 (September 1, 1995): 277–84. http://dx.doi.org/10.1042/cs0890277.

Full text

Abstract:

1. Airway epithelium in cystic fibrosis is characterized by a defect in chloride secretion across the apical membrane and an increase in sodium absorption. The increased rate of sodium absorption can be inhibited in vitro by ouabain, a Na+-K+-ATPase inhibitor, and in cystic fibrosis patients the number and activity of nasal epithelial Na+-K+-ATPase pumps is increased. 2. We have performed a series of studies to determine whether drugs which modify airway epithelial Na+-K+-ATPase activity in vitro can modify nasal potential in cystic fibrosis patients in vivo. As transepithelial nasal potential difference measurements were used to study the effect of drug modulation of airway epithelial ion transport in vivo, the repeatability of the technique was first evaluated. In order to assess the effectiveness of the technique used for measuring nasal potential difference, a pilot study was carried out using topical amiloride, a drug which has previously been shown to inhibit airway epithelium sodium transport in vivo. We then studied the effects of ouabain and digoxin, two inhibitors of Na+-K+-ATPase, and salbutamol, a drug which activates Na+-K+-ATPase, on nasal potential difference. 3. In study 1, nasal potential difference measurements were repeated on non-consecutive days in 20 patients with cystic fibrosis and 20 healthy individuals. Healthy subjects had a mean (SEM) potential difference value of −19.5 (0.9) mV, with a 95% range for a single estimate of 75–133%. In patients with cystic fibrosis, the mean (SEM) potential difference was −40.4 (2.1) mV, with a 95% range for a single estimate of 74–136%. 4. In an initial pilot study, the effect of topical amiloride on nasal potential difference was investigated on two consecutive days in four cystic fibrosis patients and four healthy control subjects, in a double-blind, placebo-controlled, randomized cross-over study. Nasal transepithelial potential was measured before and at 5, 15, 30, 45 and 60 min after the intranasal administration of 0.4 ml of a fine spray of 1 mmol/l amiloride or 0.9% saline placebo to both nostrils. Amiloride was associated with a maximal reduction in nasal potential difference at 15 min of 49% and 41% in cystic fibrosis patients and control subjects, respectively. Compared with saline, the amiloride response was significant in both groups (P < 0.025). 5. In study 2, the effect of topical ouabain and salbutamol on nasal potential difference was investigated in ten cystic fibrosis patients and ten healthy control subjects, in a double-blind, placebo-controlled, randomized cross-over study. Nasal transepithelial potential was measured before and at 5, 15, 30, 45 and 60 min after the intranasal administration of either 0.4 ml of a fine spray of 5 mg/ml salbutamol, 0.25 mg/ml ouabain or 0.9% saline placebo to both nostrils. There was no significant change in nasal potential difference with either ouabain, salbutamol or placebo in either healthy control subjects or patients with cystic fibrosis. 6. In study 3, we performed a randomized, double-blind, placebo-controlled cross-over study of oral digoxin on nasal potential difference, spirometry and sweat electrolytes for 2 weeks in 11 patients with cystic fibrosis. During the treatment period, patients had a mean (range) serum digoxin level after the first and second week of therapy of 0.9 (0.3–1.4) μg/l and 1.1 (0.4–2.2) μg/l, respectively. There was no significant difference in the change in nasal potential difference measurements, forced expiratory volume in 1 s and sweat Na/Cl concentrations between the digoxin and placebo trial periods. 7. In conclusion, neither topical ouabain nor systemic digoxin had any effect on nasal potential difference in cystic fibrosis. Inhibitors of Na+-K+-ATPase are therefore unlikely to find a role in the treatment of cystic fibrosis. The lack of a detrimental effect of salbutamol on nasal potential difference is reassuring, as β-agonists are widely used in patients with cystic fibrosis.

APA, Harvard, Vancouver, ISO, and other styles

19

Wilschanski, M., H. Famini, N. Strauss-Liviatan, J. Rivlin, H. Blau, H. Bibi, L. Bentur, et al. "Nasal potential difference measurements in patients with atypical cystic fibrosis." European Respiratory Journal 17, no. 6 (June 1, 2001): 1208–15. http://dx.doi.org/10.1183/09031936.01.00092501.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Höfmann, T., O. Bohmer, G. Hüls, H. G. Terbrack, P. Bittner, V. Klingmüller, E. Heerd, and H. Lindemann. "Conventional and modified nasal potential-difference measurement in cystic fibrosis." American Journal of Respiratory and Critical Care Medicine 155, no. 6 (June 1997): 1908–13. http://dx.doi.org/10.1164/ajrccm.155.6.9196094.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Solomon, George M., Michael W. Konstan, Michael Wilschanski, Joanne Billings, Isabelle Sermet-Gaudelus, Frank Accurso, François Vermeulen, et al. "An International Randomized Multicenter Comparison of Nasal Potential Difference Techniques." Chest 138, no. 4 (October 2010): 919–28. http://dx.doi.org/10.1378/chest.10-0179.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Tridello, Gloria, Laura Menin, Emily Pintani, Gabriella Bergamini, Baroukh Maurice Assael, and Paola Melotti. "Nasal potential difference outcomes support diagnostic decisions in cystic fibrosis." Journal of Cystic Fibrosis 15, no. 5 (September 2016): 579–82. http://dx.doi.org/10.1016/j.jcf.2016.06.009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Solomon, George M., Bo Liu, Isabelle Sermet-Gaudelus, Isabelle Fajac, Michael Wilschanski, Francois Vermeulen, and Steven M. Rowe. "A multiple reader scoring system for Nasal Potential Difference parameters." Journal of Cystic Fibrosis 16, no. 5 (September 2017): 573–78. http://dx.doi.org/10.1016/j.jcf.2017.04.011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Alton, EW, D. Currie, R. Logan-Sinclair, JO Warner, ME Hodson, and DM Geddes. "Nasal potential difference: a clinical diagnostic test for cystic fibrosis." European Respiratory Journal 3, no. 8 (September 1, 1990): 922–26. http://dx.doi.org/10.1183/09031936.93.03080922.

Full text

Abstract:

Patients with cystic fibrosis (CF) demonstrate a markedly more negative potential difference (PD) across respiratory epithelia than normal or "diseased" controls. A technique is described for the measurement of nasal PD in both children and adults. 145 non-CF subjects showed a mean PD of -19.0 mV (range -2 to -36) in comparison to 60 patients with cystic fibrosis with mean of -46.0 mV (range -32 to -77). Amongst the latter group those with more severe disease had a more negative PD. Measurement of nasal PD is easily learnt and rapidly performed and may provide an additional means of diagnosis for CF.

APA, Harvard, Vancouver, ISO, and other styles

25

Kersting, U., A. Schwab, and A. Hebestreit. "Measurement of human nasal potential difference to teach the theory of transepithelial fluid transport." Advances in Physiology Education 275, no. 6 (December 1998): S72. http://dx.doi.org/10.1152/advances.1998.275.6.s72.

Full text

Abstract:

We describe a novel student course in membrane physiology in which students record their own nasal potential difference, i.e., the transepithelial potential difference of the respiratory mucosa in the nose. The nasal potential difference monitors directly, and in vivo, changes in the apical cell membrane potential of the respiratory mucosa induced by activators and inhibitors of ion channel activities. Basic principles of transepithelial fluid transport are taught by applying an appropriate perfusion protocol to the respiratory epithelium to either depolarize or hyperpolarize the membrane potential of the luminal cell side, thereby increasing or decreasing the nasal potential difference. This course was given at the Department of Physiology at the University of Würzburg in 1997, and responses of the students as reported on questionnaires were mainly positive.

APA, Harvard, Vancouver, ISO, and other styles

26

Leonard, Anissa, Bob Lubamba, Barbara Dhooghe, Sabrina Noel, Pierre Wallemacq, Patrick Lebecque, and Teresinha Leal. "Comparative Variability of Nasal Potential Difference Measurements in Human and Mice." Open Journal of Respiratory Diseases 02, no. 02 (2012): 43–56. http://dx.doi.org/10.4236/ojrd.2012.22007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Delmarco, A., U. Pradal, G. Cabrini, A. Bonizzato, and G. Mastella. "Nasal potential difference in cystic fibrosis patients presenting borderline sweat test." European Respiratory Journal 10, no. 5 (May 1, 1997): 1145–49. http://dx.doi.org/10.1183/09031936.97.10051145.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Durie, P. R., L. Ellis, M. Corey, Knowles, L. C. Tsui, J. Zielenski, E. Tullis, and W. Ip. "NASAL TRANSEPITHELIAL POTENTIAL DIFFERENCE IN PATIENTS WITH DEFINED CFTR GENE MUTATIONS." Journal of Pediatric Gastroenterology and Nutrition 21, no. 3 (October 1995): 359. http://dx.doi.org/10.1097/00005176-199510000-00150.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

PRADAL, UGO, CARLO CASTELLANI, ANTONELLA DELMARCO, and GIANNI MASTELLA. "Nasal Potential Difference in Congenital Bilateral Absence of the Vas Deferens." American Journal of Respiratory and Critical Care Medicine 158, no. 3 (September 1998): 896–901. http://dx.doi.org/10.1164/ajrccm.158.3.9711029.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Sermet-Gaudelus, Isabelle, Emmanuelle Girodon, Frédéric Huet, Rola Aboutaam, Stéphanie Bui, Eric Deneuville, Marcel Guillot, Stéphanie Vrielynck, Gérard Lenoir, and Aleksander Edelman. "Nasal potential difference in cystic fibrosis diagnosis of very young children." Journal of Pediatrics 150, no. 3 (March 2007): e34-e35. http://dx.doi.org/10.1016/j.jpeds.2006.11.055.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Middleton, P. G., and J. R. Bishop. "368 Nasal potential difference testing in the diagnostic algorithm of CF." Journal of Cystic Fibrosis 6 (June 2007): S90. http://dx.doi.org/10.1016/s1569-1993(07)60338-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Sinaasappel, M., H. De Jonge, and I. Bronsveld. "P0289 NASAL POTENTIAL DIFFERENCE VERSUS INTESTINAL CURRENT MEASUREMENTS IN CF DIAGNOSIS." Journal of Pediatric Gastroenterology and Nutrition 39, Supplement 1 (June 2004): S167. http://dx.doi.org/10.1097/00005176-200406001-00413.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Segal, I., E. Kerem, Y. Yaacov, S. Adler, E. Broide, H. Blau, H. Bibi, et al. "P0811 THE USE OF NASAL POTENTIAL DIFFERENCE MEASUREMENTS IN RECURRENT PANCREATITIS." Journal of Pediatric Gastroenterology and Nutrition 39, Supplement 1 (June 2004): S365. http://dx.doi.org/10.1097/00005176-200406001-00935.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Vermeulen, François, Marijke Proesmans, Mieke Boon, and Kris De Boeck. "Improved repeatability of nasal potential difference with a larger surface catheter." Journal of Cystic Fibrosis 14, no. 3 (May 2015): 317–23. http://dx.doi.org/10.1016/j.jcf.2014.08.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Aalbers, Bente L., Yasmin Yaakov, Nico Derichs, Nicholas J. Simmonds, Elke De Wachter, Paola Melotti, Kris De Boeck, et al. "Nasal potential difference in suspected cystic fibrosis patients with 5T polymorphism." Journal of Cystic Fibrosis 19, no. 4 (July 2020): 627–31. http://dx.doi.org/10.1016/j.jcf.2019.07.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

House, Hugh H., and Peter G. Middleton. "Impact of different chloride and glucose solutions on nasal potential difference." Pediatric Pulmonology 44, no. 7 (July 2009): 645–48. http://dx.doi.org/10.1002/ppul.21032.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Dias, Michael A., Pathmajani Sukumar, Thomas K. Fitzgerald, Perry W. Alexion, and Rebecca Bascom. "A Sub-Irritant Pulse of Air to the Nasal Mucosa Alters Nasal Transepithelial Potential Difference in Humans." Otolaryngology–Head and Neck Surgery 113, no. 2 (August 1995): P136. http://dx.doi.org/10.1016/s0194-5998(05)80807-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Vermeulen, F., F. Vermeulen, N. Feyaerts, M. Proesmans, and K. De Boeck. "Comparison of nasal potential difference measurements done on the nasal floor and under the inferior turbinate: repeatability." Journal of Cystic Fibrosis 8 (June 2009): S10. http://dx.doi.org/10.1016/s1569-1993(09)60043-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Valiulis, Arūnas, Iveta Skurvydienė, Valdonė Misevičienė, Jūratė Kasnauskienė, Laimutė Vaidelienė, and Algirdas Utkus. "Relevance of Nasal Potential Difference in Diagnosis of Cystic Fibrosis Among Children." Medicina 49, no. 4 (May 5, 2013): 29. http://dx.doi.org/10.3390/medicina49040029.

Full text

Abstract:

Objective. The aim of this study was to estimate the significance of nasal potential difference (NPD) in the diagnosis of cystic fibrosis (CF) in children with clinical symptoms suggestive of the disease, positive sweat test results, and/or genetically confirmed diagnosis. Material and Methods. NPD measurements according to the modifications by Alton were performed in 50 children with clinical CF symptoms supported by positive sweat test results, 50 children with other obstructive lung diseases, and 50 healthy children. A subgroup of 17 children with the diagnosis confirmed by 2 identified mutations in the CF transmembrane regulatory gene was analyzed individually. Results. The mean NPD value recorded in 50 children with clinical symptoms of CF supported by positive sweat test results and/or genetic analysis was –28.0 mV [SD, 10.2]. The mean NPD value in the subgroup of children with 2 identified mutations in the CF gene (n=17) was more negative than in the subgroup of children with unrecognized mutations (n=33) (–37.1 mV [SD, 7.0] vs. –23.4 mV [SD, 8.3], P<0.001). The mean NPD value in patients with other obstructive lung diseases and healthy children was significantly more positive than in the group of CF children with positive sweat test results and/or identified mutations (–18.1 mV [SD, 3.6] and –15.5 mV [SD, 4.3] vs. –28.0 mV [SD, 10.2], P<0.001). The NPD cut point value for the genetically confirmed diagnosis of CF was –35.0 mV (sensitivity, 93.9%; specificity, 88.2%), while in general, the NPD prognostic value was –24.0 mV (sensitivity, 58.0%; specificity, 98.0%) Conclusions. The NPD measurement is a valuable tool for the diagnosis of CF in children, but further studies are necessary to establish NPD values related to the CF genotype and to reduce the intrasubject variability of this test.

APA, Harvard, Vancouver, ISO, and other styles

40

Griesenbach, Uta, Stephen N. Smith, Raymond Farley, Charanjit Singh, and Eric W. F. W. Alton. "Validation of Nasal Potential Difference Measurements in Gut-Corrected CF Knockout Mice." American Journal of Respiratory Cell and Molecular Biology 39, no. 4 (October 2008): 490–96. http://dx.doi.org/10.1165/rcmb.2007-0385oc.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Mac Sweeney, R., H. Fischer, and D. F. McAuley. "Nasal potential difference to detect Na+channel dysfunction in acute lung injury." American Journal of Physiology-Lung Cellular and Molecular Physiology 300, no. 3 (March 2011): L305—L318. http://dx.doi.org/10.1152/ajplung.00223.2010.

Full text

Abstract:

Pulmonary fluid clearance is regulated by the active transport of Na+and Cl−through respiratory epithelial ion channels. Ion channel dysfunction contributes to the pathogenesis of various pulmonary fluid disorders including high-altitude pulmonary edema (HAPE) and neonatal respiratory distress syndrome (RDS). Nasal potential difference (NPD) measurement allows an in vivo investigation of the functionality of these channels. This technique has been used for the diagnosis of cystic fibrosis, the archetypal respiratory ion channel disorder, for over a quarter of a century. NPD measurements in HAPE and RDS suggest constitutive and acquired dysfunction of respiratory epithelial Na+channels. Acute lung injury (ALI) is characterized by pulmonary edema due to alveolar epithelial-interstitial-endothelial injury. NPD measurement may enable identification of critically ill ALI patients with a susceptible phenotype of dysfunctional respiratory Na+channels and allow targeted therapy toward Na+channel function.

APA, Harvard, Vancouver, ISO, and other styles

42

Southern, Kevin W., Peadar G. Noone, Darin G. Bosworth, Vicky A. LeGrys, Michael R. Knowles, and Pierre M. Barker. "A modified technique for measurement of nasal transepithelial potential difference in infants." Journal of Pediatrics 139, no. 3 (September 2001): 353–58. http://dx.doi.org/10.1067/mpd.2001.116278.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Gowen, C. W., E. E. Lawson, J. Gingras-Leatherman, J. T. Gatzy, R. C. Boucher, and M. R. Knowles. "Increased nasal potential difference and amiloride sensitivity in neonates with cystic fibrosis." Journal of Pediatrics 108, no. 4 (April 1986): 517–21. http://dx.doi.org/10.1016/s0022-3476(86)80825-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Tümmler, B., A. Schulz, J. Rademacher, T. Welte, and F. C. Ringshausen. "ePS01.9 Nasal potential difference in adults with idiopathic non-cystic fibrosis bronchiectasis." Journal of Cystic Fibrosis 15 (June 2016): S38—S39. http://dx.doi.org/10.1016/s1569-1993(16)30196-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Yaakov, Y., R. Jaron, J. Rivlin, H. Blau, L. Bentur, Y. Yahav, E. Kerem, H. Bibi, E. Picard, and M. Wilschanski. "Nasal potential difference in non classic cystic fibrosis – long term follow up." Journal of Cystic Fibrosis 7 (June 2008): S10. http://dx.doi.org/10.1016/s1569-1993(08)60039-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Middleton, P. G., and H. H. House. "Nasal potential difference testing – the effect of different glucose and chloride concentrations." Journal of Cystic Fibrosis 7 (June 2008): S21. http://dx.doi.org/10.1016/s1569-1993(08)60080-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Schüler, P., S. Luigart, S. Prange-Schmidt, C. Geidel, K. P. Zimmer, J. Pabst, and H. Lindemann. "Duration of decreasing the nasal potential difference by amiloride-mannitol dry powder." Journal of Cystic Fibrosis 7 (June 2008): S23. http://dx.doi.org/10.1016/s1569-1993(08)60089-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Gowen, C. W., E. E. Lawson, J. Gingras-Leatherman, R. C. Boucher, and M. R. Knowles. "1399 NASAL ELECTRIC POTENTIAL DIFFERENCE AND RESPONSE TO AMILORIDE SUPERFUSION IN NEONATES." Pediatric Research 19, no. 4 (April 1985): 344A. http://dx.doi.org/10.1203/00006450-198504000-01423.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Saussereau, Emilie Lyne, Delphine Roussel, Siradiou Diallo, Laurent Debarbieux, Aleksander Edelman, and Isabelle Sermet-Gaudelus. "Characterization of Nasal Potential Difference in cftr Knockout and F508del-CFTR Mice." PLoS ONE 8, no. 3 (March 7, 2013): e57317. http://dx.doi.org/10.1371/journal.pone.0057317.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Naehrlich, Lutz, Manfred Ballmann, Jane Davies, Nico Derichs, Tanja Gonska, Lena Hjelte, Silke van Konigsbruggen-Rietschel, et al. "Nasal potential difference measurements in diagnosis of cystic fibrosis: An international survey." Journal of Cystic Fibrosis 13, no. 1 (January 2014): 24–28. http://dx.doi.org/10.1016/j.jcf.2013.08.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!